Home » FDA Approves Genzyme’s Nexviazyme for Pompe Disease
FDA Approves Genzyme’s Nexviazyme for Pompe Disease
The FDA has approved Sanofi subsidiary Genzyme’s Nexviazyme for treatment of patients aged one year and older with late-onset Pompe disease.
The rare inherited disease can lead to premature death from respiratory or heart failure.
In a study of 100 patients who were randomized to receive Nexviazyme (avalglucosidase alfa-ngpt) or another FDA-approved enzyme replacement therapy, the two treatments showed similar efficacy in improving lung function.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May